Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc. is Buy-rated: molecular glue degrader biotech with Novartis/Roche partnerships and strong Phase 1 data. Click for more on GLUE.

Read on WOBR AI →